A transcription/translation-based gene signature predicts resistance to chemotherapy in breast cancer

- A 23-gene signature was developed to predict chemoresistance of breast cancers.
- The signature could define chemoresistance in ovarian, prostate cancers, as well as leukemia.
- The signature could predict clinic outcomes in breast cancers.
- Decitabine was found to target the signature and inhibit chemoresistance.